ANI Pharmaceuticals ANIP Cortrophin Gel — Net Revenues

Similar metrics at other companies

TARSProduct sales, net — Total revenues

$145.39M+85.6%

RYTMProduct revenue, net — Total revenues

$60.11M+59.4%

BCRXProduct sales, net — Total revenues

$151.4M+5.3%

VRTXProduct revenues, net — Product revenues, net

$2.99B+8.2%

AUPHNet product sales — Revenue

$73.56M+22.7%

INCYNet sales — Total revenues

$1.1B+19.8%

Questions, answered.

What is ANI Pharmaceuticals's cortrophin gel — net revenues?

ANI Pharmaceuticals (ANIP) reported cortrophin gel — net revenues of $75.12M in Q1 2026.

How has ANI Pharmaceuticals's cortrophin gel — net revenues changed year-over-year?

ANI Pharmaceuticals's cortrophin gel — net revenues increased by 42.1% year-over-year, from $52.85M to $75.12M.

What is the long-term trend for ANI Pharmaceuticals's cortrophin gel — net revenues?

Over 2 years (2022 to 2025), ANI Pharmaceuticals's cortrophin gel — net revenues has grown at a 188.8% compound annual growth rate (CAGR), from $41.69M to $347.78M.

What does cortrophin gel — net revenues mean?

This metric represents the total gross sales of a specific pharmaceutical product line or therapeutic brand after accounting for returns, allowances, and rebates. It serves as a primary indicator of market adoption, pricing power, and commercial success for a key revenue-generating asset within the company's portfolio. Monitoring this figure helps investors assess the growth trajectory and competitive positioning of the product in its respective therapeutic category.